Wednesday, January 11, 2023 9:02:53 AM
“ Dr L admitted at the end that the data wasn’t robust and his colleagues agreed “
That is actually not correct ..
At the end of his presentation he said
At about 38:30
“ FDA said we need to repeat phase 3 study with much more robust numbers .
But CYDY was struggling with money “
And
At 39:10 he said ..
“ I don’t know any other therapeutic giving 82% mortality benefit , so if anyone need help from the government is this company ‘
Then you could hear some were agreeing here ..
And at 30:30 Dr L said ..
“ Leronlimab added to ANY OTHER drug , results were much better on the patients , then these drug alone , especially with dexamethasone “
And at 29:11 he said ..
“ my feeling was that results in our critical in CD12 were enough to get EUA .. FDA didn’t agree “
Of course FDA didn’t agree , who will be using this toxic remdesivir if we have really well working drug approved !!!
All imo
GLTA longs ..
That is actually not correct ..
At the end of his presentation he said
At about 38:30
“ FDA said we need to repeat phase 3 study with much more robust numbers .
But CYDY was struggling with money “
And
At 39:10 he said ..
“ I don’t know any other therapeutic giving 82% mortality benefit , so if anyone need help from the government is this company ‘
Then you could hear some were agreeing here ..
And at 30:30 Dr L said ..
“ Leronlimab added to ANY OTHER drug , results were much better on the patients , then these drug alone , especially with dexamethasone “
And at 29:11 he said ..
“ my feeling was that results in our critical in CD12 were enough to get EUA .. FDA didn’t agree “
Of course FDA didn’t agree , who will be using this toxic remdesivir if we have really well working drug approved !!!
All imo
GLTA longs ..
Bullish
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
